The remaining case was from a 48‐year‐old male patient receiving daratumumab, an anti‐CD38 antibody, for myeloma; grade 3 diarrhoea started 31 weeks after treatment initiation and required prednisone therapy. Here, CD38 is linked to plasma cell myeloma.